© 2020 Marker Therapeutics, Inc.
If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.
TapImmune, Inc. (NASDAQ: TPIV), today announced that Memorial Sloan Kettering Cancer Center (MSKCC) successfully completed the first safety cohort in its Phase 2 ovarian cancer study.
TapImmune, Inc. (NASDAQ: TPIV), today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients.
TapImmune, Inc. (NASDAQ: TPIV), today announced its Chairman and CEO, Dr. Glynn Wilson, will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square.